Drug Research

Understanding the Issues Relating to Chirality in Drug Research

Posted Saturday, October 07, 2006 11:00:02 AM by Blog57 Team

Research and Markets (http://www.researchandmarkets.com/reports/c43175) has announced the addition of Chirality in Drug Research to their offering. This practice-oriented handbook highlights all issues relating to chirality of pharmaceuticals, from challenges in the synthesis of these complex molecules to analytical techniques to aspects of pharmacology and drug development. It is highly useful for every medicinal chemist involved in small molecule drug development. Divided into the three main sections of synthesis, analysis and drug development, this handbook covers all stages of the drug development process, including large-scale synthesis and purification of chirally pure pharmaceuticals. The two editors from academia and a major pharmaceutical company have assembled an experienced, international team who provide first-hand practical advice and report previously unpublished data....

New River Pharma to source ADHD drug API from AMRI

Posted Friday, July 28, 2006 2:57:48 PM by Blog57 Team

Albany Molecular Research, Inc. (AMRI), a global drug discovery company, has announced, that a multi-year drug substance manufacturing agreement with New River Pharmaceuticals Inc., Financial terms were not disclosed. Under the agreement, AMRI will manufacture the active pharmaceutical ingredient, in New River's compound, NRP104, a new treatment for attention deficit hyperactivity disorder (ADHD) that is currently under review with the US Food and Drug Administration. AMRI participated with New River in the development of the chemical process to manufacture NRP104. "AMRI is delighted to continue its relationship with New River Pharmaceuticals," stated AMRI chairman, President and CEO, Thomas E. D'Ambra, PhD "We are well positioned to manufacture this compound based on our long history of manufacturing, as well as our strength in chemical development....